Star51 Capital Announces First Close of Medtech Venture Fund

Star51 Capital has announced the first close of its inaugural medtech venture fund, led by anchor commitments from Abbott and Mayo Clinic and backed by senior medtech executives, physicians and life-science professionals. The operator-led fund will invest in early- and growth-stage companies across interventional therapies, diagnostics, monitoring and the digitalization of healthcare, sourcing opportunities from the United States, Europe and the Middle East.

"Medtech is at an inflection point. Technology advancements and AI are reshaping how devices are designed, delivered, and personalized. That transformation is happening now," said Tal Wenderow, Founding Managing Partner of Star51 Capital.

The fund is led by Founding Managing Partners Adam Rosenwach and Tal Wenderow. Rosenwach brings experience in senior operating and finance roles across medtech incubators and high-growth startups, including Coridea and Deerfield Catalyst. Wenderow is the founder of Corindus Vascular Robotics and is credited with steering its $1.1 billion acquisition by Siemens Healthineers; he later served as a venture partner for a global medtech strategic. The leadership team also includes Operating Partners Raymond W. Cohen, Scott Pantel and Joe Mullings. Cohen is described as having engineered more than $5 billion in exit value as CEO and Chairman of multiple medtech companies. Scott Pantel is founder and CEO of LSI and is positioned to provide access to global medtech deal flow and strategic acquirer relationships. Joe Mullings leads The Mullings Group Companies and will contribute executive search capabilities alongside Dragonfly, a medtech marketing platform.

Star51 is structured as an "ecosystem fund" that pairs strategic capital with deep operator networks to accelerate portfolio companies through clinical validation, regulatory clearance and scaling toward broader clinical adoption. The fund leverages an internal AI platform, StarVision™, and brings together domain experts, venture partners and medtech executives who have invested their own capital as limited partners, aligning their financial interests with portfolio outcomes.

Operational advantages and strategic partnerships

• Anchor investors: Abbott and Mayo Clinic led the fund's first close.
• Target areas: interventional therapies, diagnostics, monitoring, and digital healthcare.
• Geographic scope: United States, Europe and the Middle East.
• Ecosystem assets: StarVision™ AI platform, Dragonfly marketing platform, and executive search via The Mullings Group.

"Star51 is not a traditional venture fund. It's an ecosystem built by operators, for operators," said Adam Rosenwach. "What sets Star51 apart is the caliber of our ecosystem: leading strategic investors, operating partners who have built and scaled category-defining companies, and a network that gives founders the clinical insight, commercial access, and strategic relationships they need to grow and scale."

By assembling experienced operators who have both invested personally and committed professional time, Star51 aims to offer hands-on guidance spanning clinical, commercial, regulatory and intellectual property disciplines. The fund emphasizes practical support to bring products to market and generate value across the healthcare system, using strategic acquirer relationships and proprietary market intelligence to help portfolio companies reach inflection points.

Outlook

With anchor commitments from Abbott and Mayo Clinic and a leadership bench that includes executives who have driven more than $5 billion in exits and navigated a $1.1 billion acquisition, Star51 positions itself to play a bridging role between innovation and acquisition in medtech. Its operator-led, AI-enabled approach intends to accelerate companies from clinical validation to scale, targeting investments where the convergence of medtech and AI can drive new rounds of clinical and commercial adoption.